Intuitive Surgical (NASDAQ:ISRG) Director Craig Barratt Sells 1,150 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Craig Barratt sold 1,150 shares of Intuitive Surgical stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $460.00, for a total value of $529,000.00. Following the completion of the sale, the director directly owned 1,150 shares in the company, valued at $529,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $468.52 on Friday. The firm has a market cap of $162.41 billion, a price-to-earnings ratio of 56.65, a price-to-earnings-growth ratio of 3.32 and a beta of 1.45. The stock’s 50-day moving average is $408.22 and its 200-day moving average is $432.27. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.35. The company had revenue of $3.05 billion during the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. Intuitive Surgical’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.40 earnings per share. On average, equities analysts expect that Intuitive Surgical, Inc. will post 9.37 EPS for the current year.

Institutional Trading of Intuitive Surgical

A number of hedge funds and other institutional investors have recently modified their holdings of ISRG. Three Bridge Wealth Advisors LLC increased its stake in shares of Intuitive Surgical by 10.7% in the third quarter. Three Bridge Wealth Advisors LLC now owns 629 shares of the medical equipment provider’s stock valued at $256,000 after buying an additional 61 shares during the period. Capstone Wealth Management Group LLC raised its position in shares of Intuitive Surgical by 151.5% during the third quarter. Capstone Wealth Management Group LLC now owns 3,006 shares of the medical equipment provider’s stock worth $1,344,000 after acquiring an additional 1,811 shares during the last quarter. Bingham Private Wealth LLC lifted its stake in shares of Intuitive Surgical by 22.7% in the third quarter. Bingham Private Wealth LLC now owns 842 shares of the medical equipment provider’s stock worth $342,000 after acquiring an additional 156 shares during the period. Bourne Lent Asset Management Inc. lifted its stake in shares of Intuitive Surgical by 1.1% in the third quarter. Bourne Lent Asset Management Inc. now owns 26,943 shares of the medical equipment provider’s stock worth $10,956,000 after acquiring an additional 300 shares during the period. Finally, Maryland State Retirement & Pension System lifted its stake in shares of Intuitive Surgical by 12.7% in the third quarter. Maryland State Retirement & Pension System now owns 21,500 shares of the medical equipment provider’s stock worth $8,743,000 after acquiring an additional 2,422 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Raymond James Financial reaffirmed an “outperform” rating and set a $480.00 price target on shares of Intuitive Surgical in a research report on Wednesday, October 21st. HSBC downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 price objective on the stock. in a report on Thursday, July 30th. Citigroup lowered their price objective on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating on the stock in a report on Friday, July 17th. Truist Financial cut their price objective on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Finally, Royal Bank Of Canada reduced their target price on shares of Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating for the company in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $493.54.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Da Vinci system placements rose 28% year over year to 546 in Q3 2026, while net placements increased 40%, pointing to continued demand for Intuitive Surgical’s robotic-surgery systems and expansion of its installed base. Article: ISRG System Placements Rise 28%
• Neutral Sentiment: The placements increase may reflect multisystem orders and upgrades, rather than a broad-based upswing in hospital capital-equipment budgets. That leaves open whether the strong pace can be sustained. Article: ISRG System Placements Rise 28%: Is Capital Equipment Demand Rising?
• Negative Sentiment: Two directors disclosed share sales: Gary Guthart sold 10,000 shares (0.83% of his position), and Craig Barratt sold 1,150 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which may temper—but not eliminate—their significance as a sentiment overhang. SEC filing: Gary Guthart transaction SEC filing: Craig Barratt transaction

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.